Table 1 Disease activity, B-cell status, BAFF, and APRIL at all time points in patients with SLE

Age (in years)/gender

27/F

56/F

33/F

50/F

33/F

33/F

19/F

35/F

56/F

51/F

SLAM

Baseline

25

14

7

12

4

22

9

14

12

8

Depletion

11

13

6

10

n.d.

16

11

12

9

n.d.

6 months post-treatment

8

11

4

6

4

13

n.d.

9

n.d.

1

Percentage of CD19⁺ B cells

Baseline

5

6

2

2

15

18

6

8

8

1

Depletion

bdl

bdl

bdl

bdl

n.d.

bdl

bdl

bdl

bdl

bdl

Repopulation

5

4

8

11

3

4

8

4

2

Recovery

2

6

9

18

10

n.d.

8

12

5

12 months after repopulation

8

11

11

24 months after repopulation

13

18

CD19⁺ B cells × 10⁹ per litre

Baseline

0.04

0.04

0.01

0.01

0.23

0.05

0.03

0.05

0.05

0.01

Depletion

bdl

bdl

bdl

bdl

bdl

bdl

bdl

bdl

bdl

bdl

Repopulation

0.05

0.04

0.03

0.22

0.01

n.d.

0.08

0.03

0.02

Recovery

0.01

0.04

0.04

0.36

0.03

n.d.

0.11

0.07

0.04

12 months after repopulation

0.10

0.14

0.08

24 months after repopulation

0.17

0.40

BAFF (ng/ml)

Baseline

0.71

1.83

3.72

5.94

3.29

3.05

1.96

3.28

1.33

2.59

Depletion

0.80

5.50

7.72

7.20

n.d.

5.40

n.d.

6.97

2.45

5.21

Repopulation

1.79

n.d.

16.3

4.70

4.08

n.d.

4.54

2.00

4.94

Recovery

3.98

4.47

14.1

3.03

3.30

1.46

2.60

1.41

3.95

12 months after repopulation

3.51

1.36

2.85

24 months after repopulation

2.83

2.53

APRIL (ng/ml)

Baseline

7.86

17.8

6.40

15.1

0.92

17.8

0

182

0.34

10.6

Depletion

1.56

3.02

3.15

3.53

n.d.

10.8

n.d.

176

0.99

5.75

Repopulation

8.62

n.d.

1.56

9.20

5.06

n.d.

93.9

1.24

6.65

Recovery

11.9

2.45

1.24

22.7

4.49

0

65.2

2.21

5.50

12 months after repopulation

1.62

40.9

6.46

24 months after repopulation

1.24

23.8